Sarah Krepp
Known title: Chief Human Resource OfficerCIK: 0002074990
Associated companies
Transaction History
| LQDA | ▼ Sell | Open Market | 274 | $19K | 9/1/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 558 | $40K | 7/13/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 7,306 | $523K | 7/13/2026 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 3,179 | — | 7/10/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 19,131 | $1.3M | 6/11/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 5,749 | $404K | 6/11/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 276 | $17K | 6/1/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 4,557 | $175K | 4/13/2026 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 3,179 | — | 4/10/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 16,261 | $618K | 3/13/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 276 | $8K | 3/2/2026 | View on chart |
| LQDA | ▲ Buy | Grant | 23,728 | $0 | 1/16/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 13,165 | $493K | 1/12/2026 | View on chart |
| LQDA | ▲ Buy | Option Exercise | 12,716 | — | 1/9/2026 | View on chart |
| LQDA | ▼ Sell | Open Market | 221 | $7K | 12/1/2025 | View on chart |
| LQDA | ▼ Sell | Open Market | 1,691 | $40K | 10/13/2025 | View on chart |
| LQDA | ▼ Sell | Open Market | 209 | $6K | 8/29/2025 | View on chart |
| LQDA | ▼ Sell | Open Market | 2,673 | $38K | 7/14/2025 | View on chart |
| LQDA | ▲ Buy | Grant | 25,000 | $0 | 7/1/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Liquidia shares fall on patent court loss and analyst downgrades
Liquidia stock is down sharply after a court ruling regarding YUTREPIA patent access, which analysts say clouds the drug's future. Wells Fargo downgraded the stock to Equal-Weight and lowered its price target to $30, while other analysts also cut their targets. The stock is currently trading near its 52-week low, reflecting significant market concern over the legal outcome.
Liquidia shares fall on patent court loss and analyst downgrades. Liquidia stock is down sharply after a court ruling regarding YUTREPIA patent access, which analysts say clouds the drug's future. Wells Fargo downgraded the stock to Equal-Weight and lowered its price target to $30, while other analysts also cut their targets. The stock is currently trading near its 52-week low, reflecting significant market concern over the legal outcome.